Announced Tue, 19 May · 23:17 IST

The Board of Directors at their meeting held on May 19, 2026, has approved the appointment of Mr. Ravi Gothwal as AVP- Investor Relations, who shall be classified as a Senior Management ....

Management Changes View source PDF

HCG · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.7%1-day move
₹649.50
prior close
₹632.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+2.3+3.4+3.4+2.9-2.7+0.9+1.3+1.0+1.6-0.5-3.5-5.4+0.9
Up moveDown movePending
AI summary

HCG's Board meeting on May 19, 2026 approved four personnel changes: (1) re-appointment of Rajiv Maliwal as Non-Executive Independent Director for a second 5-year term from May 25, 2026, pending shareholder approval; (2) appointment of Sanjeev Kumar as CFO and KMP from May 25, 2026, replacing CEO Dr. Manish Mattoo who held the role on an interim basis since his predecessor's departure; (3) appointment of Ravi Gothwal as AVP – Investor Relations (classified as Senior Management Personnel) from May 19, 2026; and (4) re-appointment of Vijay S. Shanbhag as Internal Auditor for one year from May 30, 2026. The new CFO Sanjeev Kumar brings over 30 years of finance leadership experience including Group CFO roles at InterGlobe Enterprises and Medanta, where he led Global Health's successful IPO. Ravi Gothwal also joins from Medanta's investor relations and M&A team.

Likely market impact

The permanent CFO appointment restores formal governance after an extended interim period, which should be viewed positively by investors. The strong external hire (CFO) with capital markets and IPO experience signals strategic intent. No immediate shareholder action required beyond ordinary approval for the independent director re-appointment.